Gleevec submitted in US and EU for first-line use in CML

被引：0
|
作者：
不详
机构：
来源：
DRUG NEWS & PERSPECTIVES | 2002年 / 15卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：337 / 337
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of imatinib (GLEEVEC) as first-line treatment in chronic myeloid leukemia (CML)
    El Quagari, K
    Talbot, W
    Baladi, JF
    VALUE IN HEALTH, 2004, 7 (06) : 669 - 669
  • [2] First-line therapy for CML: decisions, decisions
    Davies, Jeff
    LANCET HAEMATOLOGY, 2015, 2 (03): : E89 - E90
  • [3] Generational change in first-line therapy of CML
    不详
    ONKOLOGIE, 2010, 33 (12): : 715 - 715
  • [4] Dasatinib as first-line therapy for CML-CP
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2014, 15 (01): : E7 - E7
  • [5] First-line therapy for CML: nilotinib comes of age
    Davies, Jeff
    LANCET ONCOLOGY, 2011, 12 (09): : 826 - 827
  • [6] First-line use of ECT
    Bolwig, TG
    JOURNAL OF ECT, 2005, 21 (01) : 51 - 51
  • [7] Hematology: Nilotinib as first-line therapy for Ph+ CML
    Hutchinson L.
    Nature Reviews Clinical Oncology, 2010, 7 (2) : 67 - 67
  • [8] Therapy goals for first-line treatment in CML and implications for the doctor
    Saussele, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 1 - 1
  • [9] Is Imatinib Still an Acceptable First-Line Treatment for CML in Chronic Phase?
    Goldman, John M.
    Marin, David
    ONCOLOGY-NEW YORK, 2012, 26 (10): : 901 - 907
  • [10] The Three Year Follow-up of CML Patients Treated with First-line Generic and First-line Branded Imatinib in Bosnia and Herzegovina
    Islamagic, Erna
    Kurtovic, Sabira
    Kozaric, Mirza
    Hadzimesic, Emina S.
    Hasic, Azra
    Mehinovic, Lejla
    Kurtovic-Kozaric, Amina
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2017, 27 (01): : 8 - 12
12345